ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Business/EarningsArticle

Fonterra Beats Return Target in H2 2026, Eyes FY 2027 Guidance

The dairy cooperative reported that its return on capital exceeded the 10%–12% target range, citing strong stream returns and commodity tailwinds, while noting logistics challenges in the Middle East and plans for further investment.

PA
Priya Anand · Equities & Earnings Desk · 24 Sept 2026 · 01:51 · 1 min read
Share
Fonterra Beats Return Target in H2 2026, Eyes FY 2027 Guidance

Fonterra's return on capital for the second half of 2026 came in above its 10%–12% target range, which the company describes as a post‑Mainland average. Management said the result was lifted by favorable stream returns and commodity pricing relativities that acted as tailwinds, though they noted these factors are partly cyclical and may not repeat at the same level in FY 2027.

The company's shares were last quoted at $8.30, up 1.68% (+$0.12) from the previous close of $8.16, with a 52‑week high of $8.49 and a low of $6.14.

Looking ahead, Fonterra expects to track toward the midpoint of its FY 2027 guidance range if stream returns remain similar to those seen in 2026, but anticipates some reversion or normalization in the back half of the year.

Operationally, Fonterra said it continues to reliably supply customers in the Middle East despite regional tensions linked to Iran and wider disruptions. Shipments are experiencing longer transit times and higher logistics costs, although the Kotahi joint venture with Silver Fern Farms supports shipping access.

The cooperative also disclosed that it has additional investments to make, which could affect future returns in coming periods.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT